Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03809000 · ClinicalTrials.gov registry record · Phase 2
A Study of Salvage Radiotherapy With or Without Enzalutamide in Recurrent Prostate Cancer Following Surgery
A Phase 2 study of Prostate Cancer, sponsored by RTOG Foundation.
- Active
- Registry status
- Phase 2
- Development phase
- 188
- Enrollment target
- 20
- Study locations
NCT03809000 is a Phase 2 study of Prostate Cancer that is active but no longer recruiting, run by RTOG Foundation. The registered enrollment target is 188 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (69% lower). The trial reports 20 study locations across 5 states.
The verdict
NCT03809000, a Phase 2 study of Prostate Cancer, is active but no longer recruiting, sponsored by RTOG Foundation.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 188 participants
- Enrollment target
- 20
- Study locations
Study Summary
Patients with post-prostatectomy PSA (Prostate Specific Antigen) recurrences with aggressive disease features will receive salvage radiation therapy and standard androgen deprivation therapy (ADT) or enhanced ADT to determine if there is any improvement in progression-free survival when enhanced ADT is used compared to standard ADT.
Conditions Studied
Interventions
- RADIATION Radiation Therapy
- DRUG Enzalutamide
- DRUG Bicalutamide
- DRUG GnRH analog
Study Locations (20)
California
- Marin Cancer Care, Inc. - Greenbrae
- Marin Health Medical Center - Greenbrae
- University of Southern California - Los Angeles
- USC Medical Center - Los Angeles County - Los Angeles
- Cedars-Sinai Medical Center - Los Angeles
- Roseville Radiation Oncology Center - Roseville
- Sutter Roseville Medical Center - Roseville
- Sutter Medical Center Sacramento - Sacramento
- University of California, San Francisco - San Francisco
Arizona
- Arizona Center for Cancer Care - Gilbert - Gilbert
- Arizona Center for Cancer Care - Peoria - Peoria
- Arizona Center for Cancer Care - Phoenix - Phoenix
- Arizona Center for Cancer Care - Scottsdale East - Scottsdale
- Arizona Center for Cancer Care - Scottsdale North - Scottsdale
- Arizona Center for Cancer Care - Surprise - Surprise
Florida
- University of Florida Health Science Center - Gainesville
- AdventHealth Orlando - Orlando
- Moffitt Cancer Center - Tampa
Colorado
- Valley View Hospital Cancer Center - Glenwood Springs
Georgia
- Nancy N. & J.C. Lewis Cancer & Research Pavilion - Savannah
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 188 participants |
| Start Date | 2019-04-15 |
| Est. Completion | 2029-09-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03809000
The ClinicalTrials.gov registry entry for NCT03809000 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 188 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (69% lower). The listed sponsor is RTOG Foundation, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 4 interventions - of which Radiation Therapy is the first listed.
NCT03809000 reports 20 study locations spanning 5 distinct geographic areas - top geographies include California, Arizona, Florida.
Frequently Asked Questions
What is clinical trial NCT03809000 about?
NCT03809000 is a clinical study titled "A Study of Salvage Radiotherapy With or Without Enzalutamide in Recurrent Prostate Cancer Following Surgery". Patients with post-prostatectomy PSA (Prostate Specific Antigen) recurrences with aggressive disease features will receive salvage radiation therapy and standard androgen deprivation therapy (ADT) or enhanced ADT to determine if there is any improvement in progression-free survival when enhanced ADT...
What is the current status of trial NCT03809000?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 188 participants. The study started on 2019-04-15. Estimated completion is 2029-09-15.
What conditions does trial NCT03809000 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT03809000?
The interventions under investigation include: Radiation Therapy (RADIATION), Enzalutamide (DRUG), Bicalutamide (DRUG), GnRH analog (DRUG).
Who is sponsoring clinical trial NCT03809000?
This trial is sponsored by RTOG Foundation, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03809000 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
RECRUITING · Phase 2
-
Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer
RECRUITING · Phase 2
-
Post-prostatectomy Radiation Therapy--Moderate Versus Ultra-hypofractionated (Also Known as Stereotactic Body Radiation Therapy [SBRT])
RECRUITING · Phase 2
-
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
RECRUITING · Phase 2
-
Utility of Hyperpolarized 13C-pyruvate Metabolic Magnetic Resonance Imaging
RECRUITING · Phase 2
-
High Intensity Focused Ultrasound in Prostate Cancer
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.